Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer

被引：0
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 01期
关键词：
D O I：
10.1016/j.juro.2016.10.035
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
[21]   Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study). [J].
Veccia, Antonello ;
Burgio, Salvatore Luca ;
Di Lorenzo, Giuseppe ;
Ortega, Cinzia ;
Scognamiglio, Florinda ;
Aieta, Michele ;
Zustovich, Fable ;
Mattioli, Rodolfo ;
Mansueto, Giovanni ;
Facchini, Gaetano ;
Procopio, Giuseppe ;
D'Angelo, Alessandro ;
Spizzo, Gilbert ;
Donini, Maddalena ;
Bortolus, Roberto ;
Vicario, Giovanni ;
Zucali, Paolo A. ;
Basso, Umberto ;
Lo Re, Giovanni ;
Caffo, Orazio .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[22]   Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer [J].
Sonpavde, Guru ;
Huang, Ahong ;
Wang, Li ;
Baser, Onur ;
Miao, Raymond .
BJU INTERNATIONAL, 2018, 121 (06) :871-879
[23]   Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry [J].
Simon Chowdhury ;
Anders Bjartell ;
Nicolaas Lumen ;
Pablo Maroto ;
Thomas Paiss ;
Francisco Gomez-Veiga ;
Alison Birtle ;
Gero Kramer ;
Ewa Kalinka ;
Dominique Spaëth ;
Susan Feyerabend ;
Vsevolod Matveev ;
Florence Lefresne ;
Martin Lukac ;
Robert Wapenaar ;
Luis Costa .
Targeted Oncology, 2020, 15 :301-315
[24]   Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry [J].
Chowdhury, Simon ;
Bjartell, Anders ;
Lumen, Nicolaas ;
Maroto, Pablo ;
Paiss, Thomas ;
Gomez-Veiga, Francisco ;
Birtle, Alison ;
Kramer, Gero ;
Kalinka, Ewa ;
Spaeth, Dominique ;
Feyerabend, Susan ;
Matveev, Vsevolod ;
Lefresne, Florence ;
Lukac, Martin ;
Wapenaarls, Robert ;
Costa, Luis .
TARGETED ONCOLOGY, 2020, 15 (03) :301-315
[25]   Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer [J].
Maroto, Pablo ;
Solsona, Eduardo ;
Gallardo, Enrique ;
Mellado, Begona ;
Morote, Juan ;
Angel Arranz, Jose ;
Gomez-Veiga, Francisco ;
Unda, Miguel ;
Angel Climent, Miguel ;
Alcaraz, Antonio .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 :127-136
[26]   Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc) [J].
Caffo, O. ;
Maines, F. ;
De Giorgi, U. ;
Fratino, L. ;
Lo Re, G. ;
Zagonel, V. ;
D'Angelo, A. ;
Donini, M. ;
Verderame, F. ;
Ratta, R. ;
Procopio, G. ;
Campadelli, E. ;
Massari, F. ;
Gasparro, D. ;
Ermacora, P. ;
Messina, C. ;
Giordano, M. ;
Alesini, D. ;
Conteduca, V. ;
Veccia, A. ;
Galligioni, E. .
ANNALS OF ONCOLOGY, 2015, 26 :61-61
[27]   Re: Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated with Docetaxel Therapy [J].
Griebling, Tomas L. .
JOURNAL OF UROLOGY, 2020, 203 (01) :10-11
[28]   Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). [J].
Bracarda, S. ;
Sisani, M. ;
Rossi, M. ;
Galli, L. ;
Hamzaj, A. ;
Scali, S. ;
De Angelis, V. ;
Falcone, A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[29]   Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer [J].
Brian Schurko ;
William K Oh .
Nature Clinical Practice Oncology, 2008, 5 :506-507
[30]   Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer [J].
Schurko, Brian ;
Oh, William K. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (09) :506-507
12345